HUTCHMED (China) Limited

HCM

KYG4672N1198

HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs. Along with subsidiaries, the Company operates its business through two segments. The Oncology and Immunology segment is engaged in discovering, developing, and commercializing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases, including research and development activities covering drug discovery, development, manufacturing and regulatory functions as well as administrative activities to support research and development operations, also covering sales, marketing, manufacturing and distribution of drug developed from research and development activities. The Other Ventures segment is involved in other commercial businesses including the sales, marketing, manufacturing and distribution of other prescription drugs and over-the-counter pharmaceuticals as well as consumer health products.

Sector

Pharmaceuticals

Calendar

30/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for HUTCHMED (China) Limited

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.307 USD

Average target price

5.398 USD

Spread / Average Target

+25.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HUTCHMED (CHINA) LIMITED	+19.08%	3.68B
ELI LILLY AND COMPANY	+33.27%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.89%	367B
MERCK & CO., INC.	+20.22%	334B
ABBVIE INC.	+5.35%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.32%	171B

Other Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:12 16/05/2024 BST			5-day change	1st Jan Change
337 ^GBX	-0.88%		-0.30%	+19.08%

05-14	Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies	AN
05-14	Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer	MT

Hutchmed announces trials of HMPL-306 and Surufatinib cancer therapies	05-14	AN
Hutchmed Starts Phase 2/3 Trial of Surufatinib Combination Therapy in Pancreatic Cancer	05-14	MT
HUTCHMED Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China	05-14	CI
Hutchmed Starts Phase 2/3 Trials for Pancreatic Cancer Drug in China; Shares Rise 3%	05-14	MT
Hutchmed Begins Phase 3 Trials for Leukemia Medication in China	05-14	MT
HUTCHMED Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui	05-13	CI
HUTCHMED Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024	05-08	CI
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	04-26	MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	04-26	AN
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	04-26	MT
Hutchmed to Present New Data at US Cancer Research Conference	04-05	MT
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	04-05	CI
Hutchmed endometrial cancer treatment application accepted for review	04-02	AN
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	04-02	MT
HSBC in special payout on Canada sale; Astra FDA win	04-02	AN
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	04-02	CI
Sector Update: Health Care Stocks Advance Premarket Thursday	03-28	MT
Hutchmed lung cancer treatment accepted for review in China	03-28	AN
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China	03-28	MT
JD Sports backs outlook; Spirent accepts new offer	03-28	AN
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities	03-28	MT
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	03-27	CI
Hutchmed begins registration stage for sovleplenib phase 2/3 trial	03-22	AN
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug	03-22	MT
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug	03-22	MT

HUTCHMED (China) Limited

Equities

HCM